<p>尽管肿瘤学是制药行业中按收入计算最大的治疗领域，但抗肥胖药物在过去几年中吸引了最多的关注。这个细分市场仍处于起步阶段，预计在未来几年将快速增长。许多大型和小型制药公司都在寻求在这一领域产生重大影响。最成功的公司将获得可观的财务收益，并可能在此过程中实现超出市场的回报。</p>
<p>两家相对不为人知的生物科技公司正在该领域开发有前景的疗法，分别是 <strong>Terns Pharmaceuticals</strong>(TERN -7.64%) 和 <strong>Rhythm Pharmaceuticals</strong>(RYTM -2.57%)。如果这些生物科技公司能够取得实质性进展，它们的股价可能会飙升。以下是投资者需要了解的内容。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzM4MjMvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzM4MjMvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA"/></p>
<p>图片来源：Getty Images。</p>
<h2>1. Terns Pharmaceuticals</h2>
<p>Terns Pharmaceuticals 是一家小型临床阶段生物科技公司。该公司的主要候选药物之一是 TERN-601，一种中期口服 GLP-1 候选药物。Terns Pharmaceuticals 最近启动了一项为期 12 周的二期临床试验，旨在研究该药物在减肥方面的效果。预计将在第四季度获得数据。尽管几种已批准的抗肥胖药物正在产生可观的销售额，但口服药物可以解决一些尚未解决的问题。与皮下注射相比，口服药物的生产成本更低。</p>
<p>通过口服药物，制药公司将有机会扩大生产，针对更多患者，尤其是考虑到许多人对针头几乎过敏。TERN-601 仍处于中期研究阶段。根据最近竞争生物科技和制药公司在口服 GLP-1 药物方面的发展，Terns Pharmaceuticals 要想给市场留下深刻印象并不容易。然而，如果它能为 TERN-601 提供强劲的结果，Terns Pharmaceuticals 的股价可能会在今年晚些时候飙升。</p>
<p>Terns Pharmaceuticals 还有其他管线候选药物。它正在开发 TERN-501，作为潜在的代谢功能障碍相关性脂肪肝炎药物，以及作为可能增强 GLP-1 药物疗效的联合疗法。Terns Pharmaceuticals 的 TERN-701 是一种潜在的癌症疗法，目前处于一期研究阶段，预计将在第四季度发布数据。</p>
<p>也就是说，Terns 的表现将主要取决于 TERN-601 的进展。如果这款实验性药物在中期研究中失败，股价将会暴跌。因此，尽管这里有很大的上行潜力，但风险也高于平均水平。投资时需谨慎。</p>
<h2>2. Rhythm Pharmaceuticals</h2>
<p>Rhythm Pharmaceuticals 正瞄准减肥药市场的一个细分领域。该公司正在开发帮助因各种罕见病症而导致肥胖的患者的药物。Rhythm 的 Imcivree 于 2020 年首次获得批准，适用于某些蛋白质缺乏患者的体重管理。该药物的销售额并不高，但正在取得进展。在第二季度，Rhythm Pharmaceuticals 的收入增长了 66.8%，达到了 4850 万美元。</p>
<p>最近的临床进展使 Rhythm 的前景更加吸引人。它报告了 setmelanotide（Imcivree 的活性成分）在因下丘脑损伤导致肥胖患者中的三期强劲结果。Rhythm Pharmaceuticals 最近已提交了该药物在这一适应症下的监管申请。预计到年底可能会获得这一标签扩展。</p>
<p>此外，该公司的 bivamelagon 在下丘脑肥胖症的二期研究中也取得了成功。Rhythm Pharmaceuticals 计划明年启动 bivamelagon 的三期研究。bivamelagon 的一个额外优势是它是一种口服药物，而 setmelanotide 则通过皮下注射给药。bivamelagon 的强劲三期结果也可能推动股价上涨。Rhythm 的可寻址市场相对较小。</p>
<p>在 Imcivree 当前的适应症和下丘脑肥胖症潜在的新批准及标签扩展之间，该公司在其关注的地区（美国、欧洲和日本）目标患者群体可能高达 35,500 人。然而，针对这些特定病症的药物仍然存在需求——大多数体重管理药物并不针对这些病症。例如，目前没有针对下丘脑肥胖症的体重管理药物获得批准。</p>
<p>Rhythm Pharmaceuticals 可能成为这些较小体重管理市场的主导者。在此之前，我们还需考虑几项其他的二期和三期临床试验，这些试验可能会导致 setmelanotide 的更多标签扩展。Rhythm Pharmaceuticals 仍然存在一定风险。setmelanotide 或 bivamelagon 的临床或监管挫折可能会对股价产生负面影响。但如果公司能够推出 bivamelagon 并为 setmelanotide 增加新的适应症，未来五年内可能会带来出色的回报。</p>

TERN

RYTM

<p>两只低调的生物技术股票，Terns Pharmaceuticals 和 Rhythm Pharmaceuticals，因其在抗肥胖市场的潜力而受到关注。Terns 正在开发 TERN-601，一种口服 GLP-1 候选药物，预计将在第四季度公布结果，而 Rhythm 则专注于针对罕见病症的体重管理药物，收入增长达 66.8%。两家公司面临风险，但如果临床试验成功并获得监管批准，股票可能会大幅增长</p>

<p>While oncology is the largest therapeutic area in the pharmaceutical industry by revenue, the anti-obesity space has grabbed the most attention over the past couple of years. This niche is still in its infancy, though, and it is projected to grow rapidly at least through the end of the decade. Many drugmakers, both large and small, are seeking to make a significant impact in this area. The most successful ones will reap substantial financial benefits and perhaps generate market-crushing returns in the process.</p>
<div class="lb-trans"><p>尽管肿瘤学是制药行业中按收入计算最大的治疗领域，但抗肥胖药物在过去几年中吸引了最多的关注。这个细分市场仍处于起步阶段，预计在未来几年将快速增长。许多大型和小型制药公司都在寻求在这一领域产生重大影响。最成功的公司将获得可观的财务收益，并可能在此过程中实现超出市场的回报。</p>
</div><p>Two relatively unknown biotechs that are developing promising therapies in this field are <strong>Terns Pharmaceuticals</strong>(TERN -7.64%) and <strong>Rhythm Pharmaceuticals</strong>(RYTM -2.57%). These biotechs could soar provided they deliver solid progress. Here's what investors need to know.</p>
<div class="lb-trans"><p>两家相对不为人知的生物科技公司正在该领域开发有前景的疗法，分别是 <strong>Terns Pharmaceuticals</strong>(TERN -7.64%) 和 <strong>Rhythm Pharmaceuticals</strong>(RYTM -2.57%)。如果这些生物科技公司能够取得实质性进展，它们的股价可能会飙升。以下是投资者需要了解的内容。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzM4MjMvcGF0aWVudC1zZWxmLWFkbWluaXN0ZXJpbmctYS1zaG90LmpwZyZ3PTcwMA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F833823%2Fpatient-self-administering-a-shot.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>1. Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>1. Terns Pharmaceuticals</h2>
</div><p>Terns Pharmaceuticals is a small-cap, clinical-stage biotech. One of the company's leading candidates is TERN-601, a mid-stage oral GLP-1 candidate. Terns Pharmaceuticals has recently initiated a 12-week phase 2 clinical trial for this medicine in weight loss. It expects data from it in the fourth quarter. Although several approved anti-obesity medicines are generating substantial sales, an oral option could address some remaining issues. Oral pills come with lower manufacturing costs than subcutaneous injections.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals 是一家小型临床阶段生物科技公司。该公司的主要候选药物之一是 TERN-601，一种中期口服 GLP-1 候选药物。Terns Pharmaceuticals 最近启动了一项为期 12 周的二期临床试验，旨在研究该药物在减肥方面的效果。预计将在第四季度获得数据。尽管几种已批准的抗肥胖药物正在产生可观的销售额，但口服药物可以解决一些尚未解决的问题。与皮下注射相比，口服药物的生产成本更低。</p>
</div><p>With oral medications, drugmakers will have the opportunity to ramp up manufacturing and target even more patients, especially considering many are practically allergic to needles. TERN-601 is still just in mid-stage studies. And based on recent developments from competing biotech and pharmaceutical companies working on oral GLP-1 medicines, it won't be easy for Terns Pharmaceuticals to impress the market. However, if it can post strong results for TERN-601, Terns Pharmaceuticals' shares could soar later this year.</p>
<div class="lb-trans"><p>通过口服药物，制药公司将有机会扩大生产，针对更多患者，尤其是考虑到许多人对针头几乎过敏。TERN-601 仍处于中期研究阶段。根据最近竞争生物科技和制药公司在口服 GLP-1 药物方面的发展，Terns Pharmaceuticals 要想给市场留下深刻印象并不容易。然而，如果它能为 TERN-601 提供强劲的结果，Terns Pharmaceuticals 的股价可能会在今年晚些时候飙升。</p>
</div><p>Terns Pharmaceuticals does have other pipeline candidates. It is developing TERN-501 as a potential medicine for metabolic dysfunction-associated steatohepatitis and as a potential combination therapy that could enhance the efficacy of GLP-1 medicines. Terns Pharmaceuticals' TERN-701 is a potential cancer therapy in a phase 1 study, with an upcoming data readout scheduled for the fourth quarter.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals 还有其他管线候选药物。它正在开发 TERN-501，作为潜在的代谢功能障碍相关性脂肪肝炎药物，以及作为可能增强 GLP-1 药物疗效的联合疗法。Terns Pharmaceuticals 的 TERN-701 是一种潜在的癌症疗法，目前处于一期研究阶段，预计将在第四季度发布数据。</p>
</div><p>That said, Terns' performance will largely depend on progress related to TERN-601. And if this investigational medicine fails in mid-stage studies, the stock will plummet. So, although there is plenty of upside potential here, there is also above-average risk. Invest accordingly.</p>
<div class="lb-trans"><p>也就是说，Terns 的表现将主要取决于 TERN-601 的进展。如果这款实验性药物在中期研究中失败，股价将会暴跌。因此，尽管这里有很大的上行潜力，但风险也高于平均水平。投资时需谨慎。</p>
</div><h2>2. Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>2. Rhythm Pharmaceuticals</h2>
</div><p>Rhythm Pharmaceuticals is targeting a niche of the market for weight management drugs. The company is developing medicines that help patients with obesity due to various rare conditions. Rhythm's Imcivree, first approved in 2020, is indicated for weight management in patients with certain protein deficiencies. The medicine doesn't generate much sales, but it is making progress. In the second quarter, Rhythm Pharmaceuticals' revenue increased by 66.8% to $48.5 million.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals 正瞄准减肥药市场的一个细分领域。该公司正在开发帮助因各种罕见病症而导致肥胖的患者的药物。Rhythm 的 Imcivree 于 2020 年首次获得批准，适用于某些蛋白质缺乏患者的体重管理。该药物的销售额并不高，但正在取得进展。在第二季度，Rhythm Pharmaceuticals 的收入增长了 66.8%，达到了 4850 万美元。</p>
</div><p>Recent clinical progress has made Rhythm's prospects more attractive. It reported strong phase 3 results for setmelanotide (the active ingredient in Imcivree) in patients with obesity resulting from hypothalamic damage. Rhythm Pharmaceuticals recently submitted regulatory applications for the medicine in this indication. It could earn this label expansion by the end of the year.</p>
<div class="lb-trans"><p>最近的临床进展使 Rhythm 的前景更加吸引人。它报告了 setmelanotide（Imcivree 的活性成分）在因下丘脑损伤导致肥胖患者中的三期强劲结果。Rhythm Pharmaceuticals 最近已提交了该药物在这一适应症下的监管申请。预计到年底可能会获得这一标签扩展。</p>
</div><p>Elsewhere, the company's bivamelagon also aced a phase 2 study in hypothalamic obesity. Rhythm Pharmaceuticals plans to initiate phase 3 studies for bivamelagon next year. Bivamelagon has the added advantage of being an oral medicine, whereas setmelanotide is administered via subcutaneous injection. Strong phase 3 results for bivamelagon could also jolt the stock. Rhythm's addressable market is relatively small.</p>
<div class="lb-trans"><p>此外，该公司的 bivamelagon 在下丘脑肥胖症的二期研究中也取得了成功。Rhythm Pharmaceuticals 计划明年启动 bivamelagon 的三期研究。bivamelagon 的一个额外优势是它是一种口服药物，而 setmelanotide 则通过皮下注射给药。bivamelagon 的强劲三期结果也可能推动股价上涨。Rhythm 的可寻址市场相对较小。</p>
</div><p>Between Imcivree's current indications and the potential new approvals and label expansions in hypothalamic obesity, the company is targeting a potential patient population of up to 35,500 patients in the regions it is focusing on: the U.S., Europe, and Japan. However, there is also a need for medications that target these conditions specifically -- most weight management medicines don't do that. There are no therapies approved for weight management in hypothalamic obesity, for example.</p>
<div class="lb-trans"><p>在 Imcivree 当前的适应症和下丘脑肥胖症潜在的新批准及标签扩展之间，该公司在其关注的地区（美国、欧洲和日本）目标患者群体可能高达 35,500 人。然而，针对这些特定病症的药物仍然存在需求——大多数体重管理药物并不针对这些病症。例如，目前没有针对下丘脑肥胖症的体重管理药物获得批准。</p>
</div><p>Rhythm Pharmaceuticals could be the dominant player in these smaller weight management markets. That's before we add several other phase 2 and phase 3 clinical trials that could lead to even more label expansions for setmelanotide. Rhythm Pharmaceuticals remains somewhat risky. Clinical or regulatory setbacks with setmelanotide or bivamelagon could negatively impact the stock. But the company could deliver outstanding returns in the next five years, provided it can launch bivamelagon and add new indications to setmelanotide.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals 可能成为这些较小体重管理市场的主导者。在此之前，我们还需考虑几项其他的二期和三期临床试验，这些试验可能会导致 setmelanotide 的更多标签扩展。Rhythm Pharmaceuticals 仍然存在一定风险。setmelanotide 或 bivamelagon 的临床或监管挫折可能会对股价产生负面影响。但如果公司能够推出 bivamelagon 并为 setmelanotide 增加新的适应症，未来五年内可能会带来出色的回报。</p>
</div>

两只可能大幅上涨的冷门股票